Last reviewed · How we verify

NCT05665426

Infrared Thermography-based Study of the Warming Effect Difference at Waist

Completed NA Results posted Last updated 1 October 2025
What this trial tests

NA trial testing acupuncture in Health in 140 participants. Completed in 25 June 2023.

Timeline
14 April 2023
Primary endpoint
25 June 2023
25 June 2023

Quick facts

Lead sponsorThe Third Affiliated hospital of Zhejiang Chinese Medical University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment140
Start date14 April 2023
Primary completion25 June 2023
Estimated completion25 June 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The Third Affiliated hospital of Zhejiang Chinese Medical University

Who can join

Adults 18 to 60, any sex, with Health. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

ΔT at the Waist Between 30 Minutes and the Baseline. Primary · 30 minutes after the intervention has begin

The temperature difference (ΔT)at the waist between 30 minutes and the baseline.

GroupValue95% CI
AW Group0.71± 0.67
AC Group0.42± 0.60
MW Group0.43± 0.60
MC Group0.49± 0.65
δT of The Maximum Temperature in the Designated Area of the Waist After 30 Minutes. Secondary · 30 minutes after the intervention has begin

The change temperature (δT) of The maximum temperature in the designated area of the waist after 30 minutes.

GroupValue95% CI
AW Group0.570.37 – 0.77
AC Group0.410.21 – 0.60
MW Group0.410.23 – 0.59
MC Group0.480.31 – 0.66
The Temperature at the Waist Between 5 ,10 ,15 ,20 ,25, 30 Minutes and Baseline. Secondary · 5 minutes,10 minutes,15 minutes,20 minutes,25 minutes , 30 minutes after the intervention has begin

The temperature between 5 minutes,10 minutes,15 minutes,20 minutes ,25 minutes, 30 minutes and baseline.

baseline
GroupValue95% CI
AW Group34.06± 0.8
AC Group34.07± 0.88
MW Group34.16± 0.80
MC Group33.62± 0.79
5 min
GroupValue95% CI
AW Group34.32± 0.71
AC Group34.21± 0.80
MW Group34.37± 0.72
MC Group33.80± 0.90
10 min
GroupValue95% CI
AW Group34.47± 0.69
AC Group34.34± 0.73
MW Group34.47± 0.65
MC Group33.87± 0.73
15 min
GroupValue95% CI
AW Group34.55± 0.66
AC Group34.36± 0.70
MW Group34.53± 0.62
MC Group33.96± 0.75
20 min
GroupValue95% CI
AW Group34.59± 0.57
AC Group34.45± 0.68
MW Group34.53± 0.61
MC Group34.02± 0.71
25 min
GroupValue95% CI
AW Group34.9± 0.62
AC Group34.50± 0.70
MW Group34.60± 0.61
MC Group34.09± 0.71
30 min
GroupValue95% CI
AW Group34.77± 0.54
AC Group34.50± 0.70
MW Group34.59± 0.61
MC Group34.11± 0.70
ΔT at the Governor Vessel Between 30 Minutes and Baseline Secondary · 30 minutes after the intervention has begin

The temperature difference (ΔT) at the Governor Vessel between 30 minutes and baseline

GroupValue95% CI
AW Group0.490.28 – 0.70
AC Group0.680.45 – 0.91
MW Group0.480.22 – 0.74
MC Group0.410.21 – 0.60
Number of Participants Reporting a Sensation of Warmth in the Lower Back Secondary · Immediately after completion of the intervention session (within 5 minutes of needle withdrawal).

After completion of the intervention, participants completed a short questionnaire asking whether they experienced a sensation of warmth in the lower back during the intervention (response options: Yes/No). The outcome will be reported as the number and percentage of participants responding "Yes."

GroupValue95% CI
AW Group12
AC Group12
MW Group6
MC Group11

Adverse events — posted to ClinicalTrials.gov

Time frame: Immediately after completion of the intervention session (within 30 minutes of needle withdrawal).. Reporting threshold: 2.86%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

AW Group
Serious: 0/35 (0%)
Deaths: 0/35
AC Group
Serious: 0/35 (0%)
Deaths: 0/35
MW Group
Serious: 0/35 (0%)
Deaths: 0/35
MC Group
Serious: 0/35 (0%)
Deaths: 0/35
Other adverse events (1 terms — click to expand)

ReactionSystemAW GroupAC GroupMW GroupMC Group
Subcutaneous bruisingSkin and subcutaneous tissue disorders

Data from ClinicalTrials.gov NCT05665426 adverse events section.

Sponsor's own description

Low back pain is a common clinical condition, with up to 84% of adults experiencing varying degrees of low back pain. The most common form of low back pain is non-specific low back pain, which is often treated symptomatically in medicine due to its lack of etiology, which has many side effects. In contrast, acupuncture has the advantage of being practical and free of side effects. The use of acupuncture points in the lumbar region has a long history of application, as early as the《Huangdi Neijing》thousands of years ago. In the Ming Dynasty, there were summaries of the experience of " Yaobei Weizhong Qiu" (Which means the Weizhong point is closely associated with the waist). Weizhong point's efficacy in lumbar diseases (e.g., lumbar disc herniation, lumbago, sciatica, etc.) is still confirmed. One of the mechanisms is closely related to the improvement of microcirculation, which can be visualized by observing changes in infrared thermal parameters. Acupuncture and moxibustion are the most common therapies at Weizhong point, but there is a lack of research on the differences in efficacy between the two. Therefore, this study aims to collect the temperature parameters of the lumbar region in healthy subjects after acupuncture/moxibustion to estimate the difference in the therapeutic effect on the lumbar region, which can help to reveal the effect differences between acupuncture and moxibustion. As well as to provide scientific evidence to enrich the connotation of the classical theory " Yaobei Weizhong Qiu." the investigators will test the following hypotheses: 1. Hypotheses for main effects of different point selection(LU 5 and BL 40): H1: There is a significant difference in average temperature change at the waist at 30 minutes between the Weizhong(BL 40) group and the Chize(LU 5) group. H0: There is no difference in average temperature change at the waist at 30 minutes between the Weizhong(BL 40) group and the Chize(LU 5) group. 2. Hypotheses for the main effects of different interventions (acupuncture and moxibustion) H1: There is a significant difference in average temperature change at the waist at 30 minutes between the acupuncture group and the moxibustion group. H0: There is no difference in average temperature change at the waist at 30 minutes between the acupuncture and moxibustion groups.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Effect of acupuncture or moxibustion at Acupoints Weizhong (BL40) or Chize (LU5) on the change in lumbar temperature in healthy adults: A study protocol for a randomized controlled trial with a 2 × 2 factorial design.
    Zheng S, Shen Q, Lyu Z, Tian S, et al · · 2023 · cited 3× · PMID 37903112 · DOI 10.1371/journal.pone.0291536
  2. Lumbar temperature change after acupuncture or moxibustion at Weizhong (BL40) or Chize (LU5) in healthy adults: A randomized controlled trial.
    Zheng SY, Wang XY, Lin LN, Liu S, et al · · 2025 · PMID 39863500 · DOI 10.1016/j.joim.2025.01.004
  3. Effect of acupuncture or moxibustion at Acupoints Weizhong or Chize on the change in lumbar temperature in healthy adults: a study protocol for a randomized controlled trial with a 2 × 2 factorial design
    Zheng S, Shen Q, Lyu Z, Tian S, et al · · 2023 · DOI 10.21203/rs.3.rs-2793617/v1

Verify or expand the search:

Other trials of acupuncture

Trials testing the same drug.

Other recruiting trials for Health

Currently open trials in the same condition.

Other The Third Affiliated hospital of Zhejiang Chinese Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05665426.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing